Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-10
2010-10-05
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252200, C514S252110, C514S252180, C544S121000, C544S238000, C544S295000, C544S357000, C544S362000, C544S278000, C544S356000, C544S366000, C546S113000, C546S122000, C540S580000
Reexamination Certificate
active
07807671
ABSTRACT:
This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity useful for the treatment of HIV and AIDS. More particularly, the present disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof,wherein:A is selected from the group consisting of:
REFERENCES:
patent: 3135794 (1964-06-01), Archer
patent: 4791104 (1988-12-01), Picciola et al.
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5192770 (1993-03-01), Clark et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5811432 (1998-09-01), Marfat et al.
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6172085 (2001-01-01), Ohkawa et al.
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6573262 (2003-06-01), Wallace et al.
patent: 6632819 (2003-10-01), Wang et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 6900206 (2005-05-01), Kadow et al.
patent: 7037913 (2006-05-01), Wang et al.
patent: 7087610 (2006-08-01), Wang et al.
patent: 2002/0061892 (2002-05-01), Wang et al.
patent: 2003/0069266 (2003-04-01), Wang et al.
patent: 2003/0207910 (2003-11-01), Wang et al.
patent: 2003/0236277 (2003-12-01), Kadow et al.
patent: 2004/0063744 (2004-04-01), Wang et al.
patent: 2004/0063746 (2004-04-01), Regueiro-Ren et al.
patent: 2004/0110785 (2004-06-01), Wang et al.
patent: 2004/0186292 (2004-09-01), Wang et al.
patent: 2005/0075364 (2005-04-01), Yeung et al.
patent: 2005/0090522 (2005-04-01), Wang et al.
patent: 2005/0124623 (2005-06-01), Bender et al.
patent: 2005/0209246 (2005-09-01), Ueda et al.
patent: 2005/0215543 (2005-09-01), Lin et al.
patent: 2005/0215544 (2005-09-01), Lin et al.
patent: 2005/0215545 (2005-09-01), Lin et al.
patent: 2005/0267130 (2005-12-01), Ruediger et al.
patent: 2006/0100209 (2006-05-01), Gu et al.
patent: 2006/0100432 (2006-05-01), Matiskella et al.
patent: 2006/0142298 (2006-06-01), Kadow et al.
patent: 2007/0078141 (2007-04-01), Wang et al.
patent: 2007/0249579 (2007-10-01), Wang et al.
patent: 2007/0249624 (2007-10-01), Bachand et al.
patent: 0379314 (1990-07-01), None
patent: 0484071 (1992-05-01), None
patent: 0530907 (1993-03-01), None
patent: 1069111 (2001-01-01), None
patent: WO 93/01181 (1993-01-01), None
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 97/24350 (1997-07-01), None
patent: WO 98/28292 (1998-07-01), None
patent: WO 99/24065 (1999-05-01), None
patent: WO 9967237 (1999-12-01), None
patent: WO 00/00201 (2000-01-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/51984 (2000-09-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 00/76521 (2000-12-01), None
patent: WO 01/22954 (2001-04-01), None
patent: WO 01/62255 (2001-08-01), None
patent: WO 02/04440 (2002-01-01), None
patent: WO 02/10152 (2002-02-01), None
patent: WO 02/062423 (2002-08-01), None
patent: WO 02/085301 (2002-10-01), None
patent: WO 03/041644 (2003-05-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/082881 (2003-10-01), None
patent: WO 03/092695 (2003-11-01), None
patent: WO 03/103607 (2003-12-01), None
patent: WO 2004/000210 (2003-12-01), None
patent: WO 2004/011425 (2004-02-01), None
patent: WO 2004/043337 (2004-05-01), None
patent: 2005/004801 (2005-01-01), None
patent: WO 2005/016344 (2005-02-01), None
patent: WO 2005/121094 (2005-12-01), None
Drug Evaluations by American Medical Association (6th Ed.), pp. 1615-1616 (1986).
Heimbach, et al, “Absorption Rate Limit Considerations for Oral Phosphate Prodrugs,” Pharmaceutical Research, 20(6), pp. 848-856, 2003.
Stella, et al, Pharmacokinetics of Drug Targeting: Specific Implications for Targeting Via Prodrugs, Handbook of Experimental Pharmacology, Chapter 4, pp. 71-103, 1991.
Zhu, et al, “A One-Pot Synthesis of Nitrogen-Containing Heteroaryl α-Keto Amides from Heteroaryl Halides,” Tetrahedron Letters, 46(20), pp. 3587-3589, 2005.
Yin, et al., “Simulated PXRD Patterns in Studies of the Phase Composition and Thermal Behavior of Bulk Crystalline Solids,” American Pharmaceutical Review, 2003, 6, 2, pp. 80-85.
Hotoda, “Small-Molecule Inhibitors of HIV-1 Entry Via Chemokine Receptors,” Drugs of the Future, 24(12), pp. 1355-1362, 1999.
Sodroski, “HIV-1 Entry Inhibitors in the Side Pocket,” Cell, 9, pp. 243-246, 1999.
Blair, et al, “HIV-1 Entry-An Expanding Portal for Drug Discovery,” Drug Discovery Today, 5(5), pp. 183-194, 2000.
Font, et al, “Indoles and Pyridazinol[4,5-b]indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
Romero, et al, J. Med. Chem., 36, pp. 1505-1508, 1993.
Young, et al, “2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase,” Bioorg. Med. Chem. Lett., 5(5), pp. 491-496, 1995.
Genin, et al, “Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs,” J. Med. Chem., 39, pp. 5267-5275, 1996.
Silvestri, et al, Antiviral Chem. Chemother., 9, pp. 139-148, 1998.
Fredenhagen, et al, “Semicochliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinease Related to Asterriquinones Produced by the Fungus Chrysosporium Merdarium,” J. of Antibiotics, 50, pp. 395-401, 1997.
Wang, et al., Org. Biol. Chem., 2005, 3, pp. 1781-1786.
Meanwell et al., Current Opinion in Drug Discovery and Development, 2003, 6, 4, pp. 451-461.
Dueweke, et al, “The Binding of a Novel Bisheteroarylpiperazine Mediates Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase,” J. Biol. Chem., 267(1), pp. 27-30, 1992.
Dueweke, et al, “U-90152, a Potent Inhibitor of Human Immunodeficiency Virus Type 1 Replication,” Antimicrob. Agent, Chemother., 37(5), pp. 1127-1131, 1993.
Kato, et al, “New 5-HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives,” Chem. Pharm. Bull., 43(8), pp. 1351-1357, 1995.
Levacher, et al, “Broadening in the Scope of NADH Models by Using Chiral and Non Chiral Pyrrolo [2,3-b]Pyridine Derivatives,” Tetrahedron, 47(3), pp. 429-440, 1991.
Resnyanskaya, et al, “A Simple Synthesis of 1-Acyl-3-Aryl-3H-Pyrrolo[2′,3′:4,5]Pyrimido[6,1-b]Benzothiazol-6-ium-2-olates: Betainic Derivates of a Novel Heterocyclic System,” Synthesis, 18, pp. 2717-2724, 2002.
Carini David J.
Han Ying
Kadow John F.
Meanwell Nicholas A.
Regueiro-Ren Alicia
Bernhardt Emily
Bristol--Myers Squibb Company
Levis John F.
LandOfFree
Diketo-piperazine and piperidine derivatives as antiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diketo-piperazine and piperidine derivatives as antiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diketo-piperazine and piperidine derivatives as antiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160199